You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CTLA-4 Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • SBRT, Fruquintinib, Cadonilimab
  • Wuhan, Hubei, China
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Synovial Sarcoma Trial in New York (ipilimumab)

Terminated
Has Results
  • Synovial Sarcoma
  • ipilimumab
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Jun 23, 2021

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 31, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)

Not yet recruiting
  • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 8, 2023

Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

Active, not recruiting
  • Hepatocellular Carcinoma
  • AK104 lenvatinib
  • AK104
  • Hangzhou, Zhejiang, China
    The first affilited hospital zhejiang university school of medci
Oct 17, 2022

Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Brussels, Barcelona, Madrid (JK08)

Recruiting
  • Cancer
  • +6 more
  • Brussels, Belgium
  • +3 more
Jan 30, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cadonilimab
  • transjugular intrahepatic portosystemic shunt (TIPS)
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Solid Tumor Trial in China (SI-B003)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +7 more
Jan 11, 2023

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in China (Cadonilimab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Bengbu, Anhui, China
  • +12 more
Dec 13, 2022

Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)

Completed
  • Endometrial Cancer
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases Trial in United States (Botensilimab, Balstilimab)

Recruiting
  • Advanced Cancer
  • +7 more
  • Scottsdale, Arizona
  • +14 more
Sep 15, 2022

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Cholangiocarcinoma, Intrahepatic, PD-L1, CTLA4 Trial in Shanghai (PD-L1 antibody combined with CTLA-4 antibody)

Not yet recruiting
  • Cholangiocarcinoma, Intrahepatic
  • +2 more
  • PD-L1 antibody combined with CTLA-4 antibody
  • Shanghai, China
    Zhongshan hospital
Nov 17, 2020

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland

Not yet recruiting
  • Locally Advanced Thyroid Gland Anaplastic Carcinoma
  • +2 more
  • Chicago, Illinois
  • +1 more
Jul 7, 2022